What's in Sermonix Pharmaceuticals Inc.'s pipeline?

Sermonix Pharmaceuticals Inc. has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sermonix Pharmaceuticals Inc.'s portfolio?

Top competitors by shared drug class: Shandong Suncadia Medicine Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sermonix-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sermonix Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Sermonix Pharmaceuticals Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Fulvestrant in combination with abemaciclib	Fulvestrant in combination with abemaciclib	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and CDK4/CDK6	Oncology
Lasofoxifene in combination with abemaciclib	Lasofoxifene in combination with abemaciclib	phase 3	SERM + CDK4/6 inhibitor combination	Estrogen receptor (ER) + CDK4/6	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Shandong Suncadia Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sermonix Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Sermonix Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sermonix-pharmaceuticals-inc. Accessed 2026-05-16.